Charles Russell Speechlys advises Kreos Capital on €20 million growth capital facility in Medtech company
Charles Russell Speechlys have advised Kreos Capital on its additional growth capital facility of €20 million in Cellnovo Limited (“Cellnovo”), the wholly-owned subsidiary company of Cellnovo Group SA, a Med Tech company marketing the first mobile, connected, all-in-one diabetes management system, listed on Euronext Paris. This is a follow on facility by Kreos subsequent to its €7 million growth capital facility in 2015 and its €5 million growth capital facility in 2017.
The Charles Russell Speechlys core team comprised Chris Putt (Partner), Rossana Conti (Legal Director), Amelly Kok (Associate) and Dafni Loizou (Associate) from our Corporate Team, and Paul Kay (Partner) from our Banking Team. Foreign counsel who have advised on this transaction are Reinhart Marville Torre (French law).
News & Insights
Q&A: Consequences of the registration gap
Louise Clark and Nic Taggart answer queries relating to lease termination and rent arrears.
ESG: what does it mean and why is it important for you?
Companies operating in almost every sector are now coming under pressure to report on their ESG credentials and policies.